Logo
x

Search

Subscribe Now

Clinical trial

4 Steps To Ensure Clinical Trial Compliance

4 Steps To Ensure Clinical Trial Compliance

  • April 26, 2023
Astellas and BMT CTN Report P-III Trial (MORPHO) Results of Gilteritinib for the Treatment of Acute Myeloid Leukemia

Astellas and BMT CTN Report P-III Trial (MORPHO) Results of Gilteritinib for the Treatment of Acute Myeloid Leukemia

  • March 9, 2023
Viatris and Biocon Launch Semglee (insulin glargine-yfgn) and Insulin Glargine (insulin glargine-yfgn) for the Treatment of Diabetes in the US

Viatris and Biocon Launch Semglee (insulin glargine-yfgn) and Insulin Glargine (insulin glargine-yfgn) for the Treatment of Diabet...

  • November 17, 2021
Innovent Presented Results of IBI302 in P-Ib Clinical Trial for the Treatment of Neovascular Age-Related Macular Degeneration at AAO 2021

Innovent Presented Results of IBI302 in P-Ib Clinical Trial for the Treatment of Neovascular Age-Related Macular Degeneration at A...

  • November 15, 2021
PharmaShots Interview: Recce Pharmaceuticals' James Graham Shares Insight on the P-I/II Clinical Trial of RECCE 327 (R327) for Infected Burn Wounds

PharmaShots Interview: Recce Pharmaceuticals' James Graham Shares Insight on the P-I/II Clinical Trial of RECCE 327 (R327) for Inf...

  • September 14, 2021
Novartis Reports Results of Beovu (brolucizumab) in P-III KITE & KINGFISHER Trials for the Treatment of Diabetic Macular Edema

Novartis Reports Results of Beovu (brolucizumab) in P-III KITE & KINGFISHER Trials for the Treatment of Diabetic Macular Edema

  • August 18, 2021
PharmaShots Weekly Snapshots (March 24, 2025 – March 28, 2025) 

    PharmaShots Weekly Snapshots (March 24, 2025 – March 28, 2025) 

    • March 28, 2025
    Merck Presents P-III (3475A-D77) Trial Data of SC Keytruda for NSCLC at ELCC 2025

      Merck Presents P-III (3475A-D77) Trial Data of SC Keytruda for NSCLC at ELCC 2025

      • March 28, 2025
      Johnson & Johnson Reports P-III (MARIPOSA) Trial Data of Rybrevant + Lazcluze for EGFRm NSCLC

        Johnson & Johnson Reports P-III (MARIPOSA) Trial Data of Rybrevant + Lazcluze for EGFRm NSCLC

        • March 27, 2025
        Axsome Therapeutics Reports P-III (FOCUS) Trial Data of Solriamfetol for Attention Deficit Hyperactivity Disorder (ADHD)

          Axsome Therapeutics Reports P-III (FOCUS) Trial Data of Solriamfetol for Attention Deficit Hyperactivity Disorder (ADHD)

          • March 26, 2025
          AstraZeneca to Highlight Tagrisso’s Clinical Data for NSCLC at ELCC 2025

            AstraZeneca to Highlight Tagrisso’s Clinical Data for NSCLC at ELCC 2025

            • March 25, 2025
            PharmaShots Weekly Snapshots (March 17, 2025 – March 21, 2025) 

              PharmaShots Weekly Snapshots (March 17, 2025 – March 21, 2025) 

              • March 21, 2025
              Image

              Incisive News in 3 Shots.

              Contact Us

              Our Information

              Follow Us

              Copyright © 2025 PharmaShots - All Rights Reserved.